Director sold ~$567K of Puma Biotechnology
Scheduled in advanceLoading…
PBYI · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Los Angeles, Ca.
In the last 90 days, no insider of Puma Biotechnology reported an open-market purchase and 5 open-market sales worth about $1.12M. Every figure links to its official SEC, House, Senate or USAspending record.
Revenue
$56.5M
+7.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$41.2M
This quarter $1.62M, a year earlier $14.1M
Net cash
$36.5M
Debt $0, cash $36.5M, at Jun 30, 2026
Net income, last 12 months
$26.7M
Operating profit covers interest 8.6x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
5 sales
$1.12M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$228M
−0.9% vs the year before
Net income, fiscal 2025
$31.1M
As reported in the annual filing
Shares outstanding
51.6M
As of Aug 3, 2026
Director sold ~$567K of Puma Biotechnology
Scheduled in advanceDirector sold ~$46K of Puma Biotechnology
Scheduled in advanceCEO sold ~$364K of Puma Biotechnology
Scheduled in advanceOfficer sold ~$70K of Puma Biotechnology
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.